SEC Company Response from enVVeno Medical Corp (NVNO, NVNBW) (CIK 0001661053) (NVNO) — Apr 15, 2020
enVVeno Medical Corp (NVNO, NVNBW) (CIK 0001661053)
Date: April 15, 2020 · CIK: 0001661053 · Accession: 0001493152-20-006434
AI Filing Summary & Sentiment
Letter
VIA EDGAR Division of Corporate Finance Re: Hancock Jaffe Laboratories, Inc. Registration Statement on Form S-3 Filed April 7, 2020 File No. 333- 237592
Dear Ms. Sarmento:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Hancock Jaffe Laboratories, Inc., hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 4:30 p.m. EST on Thursday, April 16, 2020, or as soon as thereafter practicable.
Very
truly yours,
/s/
Robert A. Berman
Show Raw Text
CORRESP
1
filename1.htm
Hancock
Jaffe Laboratories, Inc.
70
Doppler
Irvine,
California 92618
April
15, 2020
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporate Finance
100
F Street, N.E.
Mail
Stop 4628
Washington,
DC 20549
Attn:
Ada D. Sarmento
Re:
Hancock
Jaffe Laboratories, Inc.
Registration
Statement on Form S-3
Filed
April 7, 2020
File
No. 333- 237592
Dear
Ms. Sarmento:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Hancock Jaffe Laboratories, Inc., hereby requests acceleration of
effectiveness of the above referenced Registration Statement so that it will become effective at 4:30 p.m. EST on Thursday,
April 16, 2020, or as soon as thereafter practicable.
Very
truly yours,
/s/
Robert A. Berman
By:
Robert A. Berman
Title:
Chief Executive Officer
cc:
Ellenoff
Grossman & Schole LLP